Three days at a trade show can compress months of first conversations into a single week. BrightMD Fair China 2026, held September 21-23 at the Shenzhen World Exhibition & Convention Center (Futian), gave Sekbio exactly that: a chance to put its small molecule hapten derivatives, custom synthesis services, and CDMO one-stop solution in front of IVD manufacturers, pharmaceutical teams, and upstream partners face to face.
The response was strong. Visitors at our booth and at our CDMO presentation showed broad interest in all three offerings, and the feedback was consistently positive. This recap covers what we showed, why small molecule derivatives were such a focus, and how partners can follow up. If you missed our BrightMD Fair China 2026 preview, it has the event background.
1. What Sekbio Showcased in Shenzhen
Sekbio exhibited as a specialized IVD immunoreagent company, and our booth was organized around three offerings that address the same underlying problem: turning a diagnostic idea into a manufacturable, high-performing raw material.
- Small molecule hapten derivative products — a product series covering vitamin B12 (cyanocobalamin), folic acid, progesterone, and estradiol derivatives and their conjugated antigens
- Custom hapten derivative services — derivatization-site design, synthesis, and carrier-protein conjugation tailored to a partner's target and assay format
- CDMO one-stop solution — a single connected pipeline from product optimization through raw-material engineering and manufacturing scale-up
Our booth panel also introduced the company itself: a high-tech enterprise focused on in vitro immunodiagnostic reagent R&D, production, and sales, operating 100,000-class and 10,000-class GMP clean rooms, with a team that has led dozens of full-process IVD reagent projects from development to launch.
2. Small Molecule Hapten Derivatives: The Product Series on Display
A hapten derivative is a small molecule, such as a vitamin, steroid hormone, or drug metabolite, that has been chemically modified at a specific site so it can be coupled to a carrier protein. Haptens are too small to trigger an immune response by themselves, so the derivative and its carrier conjugate (commonly BSA, OVA, or KLH) are what make antibody generation and competitive immunoassays possible.
The derivatives on our panel are built around Sekbio's AI-driven synthesis approach. Machine-learning models support three steps that traditionally rely on repeated trial and error:
- Structure design — proposing derivative structures that keep the key epitope of the parent molecule exposed
- Coupling-site prediction — identifying the derivatization site most likely to preserve antibody recognition
- Synthetic route optimization — screening routes and reaction conditions to shorten the conventional trial-and-error cycle
Why the derivative matters so much: in a competitive immunoassay, the antibody only sees the hapten as presented on the carrier. A derivative that hides the key epitope, or that couples at a poorly chosen position, produces antibodies with weak affinity or unwanted cross-reactivity. This is especially relevant for structurally similar molecules such as the steroid hormones progesterone and estradiol, where subtle differences in presentation decide whether an assay can tell them apart. Stability is the second concern: a derivative and its conjugate must survive synthesis, purification, and storage without degrading, or batch consistency suffers.
| Derivative Series | What It Supports | Platforms |
|---|---|---|
| Vitamin B12 (cyanocobalamin) | Derivatives and conjugated antigens for B12 immunoassays | CLIA, ELISA, colloidal gold |
| Folic acid | Derivatives and conjugated antigens for folate immunoassays | CLIA, ELISA, colloidal gold |
| Progesterone | Steroid hormone derivatives and conjugated antigens | CLIA, ELISA, colloidal gold |
| Estradiol | Steroid hormone derivatives and conjugated antigens | CLIA, ELISA, colloidal gold |
For technical detail on individual series, see our guides to vitamin B12 derivative selection and progesterone antibody pair design, or the product pages for VB12 intrinsic factor and BSA tracer conjugate, progesterone antibody, and estradiol monoclonal antibody.
"In hapten-based immunoassays, the derivatization site is rarely the obvious one. Choosing it well is what separates a sensitive, stable reagent from a months-long optimization cycle."
3. Custom Hapten Derivative Services
Many visitors arrived with a specific target rather than a catalogue request: a small molecule that no off-the-shelf derivative covers, or an existing reagent with sensitivity or stability problems. That is the use case our custom service is built for.
Custom projects typically move through four stages:
- Target and assay review — the molecule, the intended platform (CLIA, ELISA, or colloidal gold), and the sensitivity requirement
- Derivatization-site and linker design — selecting where and how the hapten is modified
- Synthesis — producing the derivative along an optimized route
- Carrier conjugation — coupling to BSA, OVA, or KLH at a controlled conjugation ratio
The custom service is most useful for three groups: IVD manufacturers whose small molecule assays underperform on sensitivity or stability, startups that hold a new small molecule biomarker but have no in-house synthesis capability, and research teams that need a well-characterized conjugated antigen to support antibody generation. In each case the goal is the same: a reagent that performs consistently and can be reproduced at scale.
IVD Application Note
Derivatization site, linker chemistry, and hapten-to-carrier ratio all influence antibody affinity. If an existing hapten reagent shows low sensitivity or poor stability, revisiting the derivative design is often more effective than tuning assay conditions.
4. The CDMO One-Stop Solution
Sekbio's CDMO one-stop solution is designed for teams that hold a new biomarker target, a granted patent, or a validated research reagent, but lack the industrialization capability to turn it into a manufacturable IVD raw material. Instead of handing the project between vendors, we carry it through one pipeline:
- Product optimization — translating a research-stage antibody pair, antigen, or hapten conjugate into an IVD-grade reagent with documented sensitivity, specificity, and batch consistency
- Recombinant antibody and raw-material engineering — building the monoclonal antibody, recombinant antigen, or small molecule derivative the finished product depends on
- Production line setup and scale-up — establishing compliant manufacturing so the reagent can be produced at commercial volume with consistent quality
- After-sales technical support — ongoing support once the raw material is in a customer's hands
| Consideration | Fragmented Vendors | CDMO One-Stop Solution |
|---|---|---|
| Accountability | Split across several vendors | One team from optimization to scale-up |
| Data handoffs | Re-transferred at every stage | Kept in one project file |
| Quality system | Different standards per vendor | One ISO 13485-certified system |
| Batch consistency | Harder to trace across sites | Traceable from raw material to release |
The model rests on the same platform that supports our protein products: mammalian expression for antibodies and antigens (see the monoclonal antibody development platform) and chemical synthesis for small molecule derivatives. Partners can start with a single component and extend into the full pipeline later. Our Diagmand 2026 recap covers the CDMO model in more depth.
5. Visitor Response and Next Steps
Across the three days, visitors engaged with the hapten derivative series, the custom service, and the CDMO model, and the feedback was consistently positive. Many conversations ended with a concrete follow-up: a datasheet request, a sample discussion, or a scoping call for a custom project.
If we spoke in Shenzhen, our team will follow up on the items we discussed. If we didn't meet, the same team is available year-round:
- Request datasheets or samples for the hapten derivative and antibody product range
- Send us a target molecule for a custom derivative feasibility review through Sekbio's contact page
- Discuss a CDMO engagement for a new biomarker target or granted patent
6. Frequently Asked Questions: BrightMD Fair China 2026 Recap
What did Sekbio showcase at BrightMD Fair China 2026?
At BrightMD Fair China 2026 in Shenzhen (September 21-23), Sekbio showcased three offerings: its small molecule hapten derivative product series (including vitamin B12, folic acid, progesterone, and estradiol derivatives and their conjugated antigens), custom hapten derivative design and synthesis services, and its CDMO one-stop solution for IVD raw materials. Visitors responded with strong interest across all three.
What are small molecule hapten derivatives?
A hapten is a small molecule, such as a steroid hormone, vitamin, or drug metabolite, that is too small to trigger an immune response on its own. A hapten derivative is the same molecule chemically modified at a chosen site so it can be coupled to a carrier protein such as BSA, OVA, or KLH. The resulting conjugated antigen is used to raise antibodies or as a coating or competition reagent in immunoassays.
Which immunoassay platforms are Sekbio's hapten derivatives designed for?
Sekbio's hapten derivative and conjugated antigen products are designed for immunoassay development on chemiluminescence (CLIA), enzyme-linked immunosorbent assay (ELISA), and colloidal gold lateral flow platforms. The right derivative depends on the assay format, so the team recommends confirming the derivatization site and carrier choice against your platform before scaling up.
Can Sekbio design a custom hapten derivative for my target?
Yes. Sekbio offers custom hapten derivative services that cover derivatization-site design, synthesis, and carrier-protein conjugation. Because derivatization site, linker chemistry, and conjugation ratio all influence antibody affinity and assay sensitivity, each project starts with a review of your target molecule and intended assay format before a route is proposed.
What is Sekbio's CDMO one-stop solution?
Sekbio's CDMO one-stop solution carries an IVD raw-material project through one connected pipeline: product optimization, recombinant antibody and raw-material engineering, production line setup and manufacturing scale-up, and after-sales technical support. Keeping these stages under one team and one ISO 13485-certified quality system avoids the handoffs between separate vendors where timelines and quality control usually slip.
How can I follow up with Sekbio after the exhibition?
Email info@sekbio.com or call +86-13590345917 to request product datasheets, discuss a custom hapten derivative project, or scope a CDMO engagement. You can also review Sekbio's antibody and antigen development platform before reaching out, and a technical team member will follow up on your project requirements.
7. Summary
- Sekbio exhibited at BrightMD Fair China 2026 (September 21-23, Shenzhen) with three offerings: hapten derivative products, custom services, and a CDMO one-stop solution.
- The derivative series covers vitamin B12, folic acid, progesterone, and estradiol, supported by AI-driven structure design, coupling-site prediction, and route optimization.
- Custom services address targets that no catalogue derivative covers, or reagents held back by low sensitivity or stability.
- The CDMO model connects product optimization, raw-material engineering, scale-up, and after-sales support under one team.
- Visitor feedback was consistently positive, and follow-up conversations are under way.
To continue a conversation from Shenzhen, or to start one, explore the Sekbio antibody and antigen development platform or contact the team directly.